“On pricing, we expect less net price erosion than we've experienced historically.”

In context

“y 13% volume growth. As you heard from Bob, 15 products delivered double-digit or better growth, a clear demonstration of the strength of our portfolio and quality of our execution. Turning to General Medicine. Repatha delivered $696 million in the second quarter, up 31% year-over-year. Improved access is enabling more patients to benefit from Repatha with an estimated 100 million people in need of effective LDL-C lowering, the opportunity to expand our impact remains substantial. In the U.S., we saw continued demand growth across both cardiology and primary care, supported by an expanding prescriber base and deepening engagement across key customer segments. Our direct-to-consumer campaign continues to make a positive impact with more patients actively asking their doctors about Repatha. On pricing, we expect less net price erosion than we've experienced historically. EVENITY sales increased 32% year-over-year to $518 million in the second quarter. In the U.S., EVENITY grew 41% with increased prescription volume from both established and newly activated prescriber accounts. In Japan, EVENITY is positively impacting many people with over 700,000 patients treated since launch. As the only therapy that both builds bone and slows bone loss, EVENITY is uniquely positioned to reduce fracture risk in women who are postmenopausal. Approximately 250,000 patients in the U.S. have been treated with EVENITY to date. However, many remain at high risk of fracture, with about 90% of the roughly 2 million very high-risk patients still not receiving appropriate therapy. This represents a meaningful opportunity to drive growth by ensuring more patients receive the prote”